WCM
ATHE

Westend Capital Management’s Alterity Therapeutics ATHE Stock Holding History

Westend Capital Management’s Portfolio ATHE Stock Details ATHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-41
Closed -$5K – 102
2014
Q3 		$5K Buy
+41
New +$5.49K 0.01% 90

Other funds holding ATHE

VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
GBA
Garrison Bradford & Associates New York $88.4M AUM 15.86% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
CAM
Columbia Asset Management Ann Arbor, Michigan $575M AUM 29.81% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Westend Capital Management's ATHE Position: Q4 2014 in Review

Westend Capital Management sold out of Alterity Therapeutics (ATHE) in Q4 2014, closing a stake of 41 shares — an estimated $5K sold.

Westend Capital Management first reported a position in ATHE in Q3 2014 and held it in 1 quarter. The position peaked at $5K in Q3 2014. 24 funds tracked by Wall St. Rank hold ATHE as of Q4 2014.

  • Westend Capital Management reported no remaining Alterity Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Westend Capital Management sold 41 Alterity Therapeutics shares in Q4 2014, an estimated $5K.
  • Westend Capital Management first reported a position in Alterity Therapeutics in Q3 2014 and held it in 1 quarter.
  • Westend Capital Management's Alterity Therapeutics position peaked at $5K in Q3 2014.
  • 24 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q4 2014.

Based on Westend Capital Management's 13F filing for Q4 2014, filed 13 Feb 2015.